Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

David Julian Sermer, M.D.

Concepts (64)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Lymphoma, Large B-Cell, Diffuse5202213031.500 Why?
Antigens, CD19320223481.010 Why?
Receptors, Antigen, T-Cell2202224970.860 Why?
Waldenstrom Macroglobulinemia2202210010.590 Why?
Immunotherapy, Adoptive2202210310.540 Why?
Proto-Oncogene Proteins c-myc120209970.530 Why?
Lymphoma1201918890.390 Why?
Mandibulofacial Dysostosis12007390.340 Why?
T-Lymphocytes32022103800.330 Why?
Limb Deformities, Congenital120071320.310 Why?
Epigenesis, Genetic1201934580.290 Why?
Prenatal Diagnosis1200711620.200 Why?
Abnormalities, Multiple1200713850.190 Why?
Proto-Oncogene Proteins c-bcl-6120202020.190 Why?
Myeloid Differentiation Factor 88120225570.170 Why?
Antineoplastic Agents12019137310.150 Why?
Lymphoma, B-Cell120229310.140 Why?
Methotrexate1202117230.130 Why?
Proto-Oncogene Proteins c-bcl-21202013880.120 Why?
Genetic Engineering120199560.120 Why?
Central Nervous System Neoplasms120218700.120 Why?
Antineoplastic Combined Chemotherapy Protocols32021113170.100 Why?
Antigens, Neoplasm1201920030.100 Why?
Anticarcinogenic Agents120122610.100 Why?
Research1201920180.100 Why?
B-Lymphocytes1202249190.090 Why?
Protein Kinase Inhibitors2202254820.090 Why?
Retrospective Studies42021722530.070 Why?
Humans1120227151180.070 Why?
Drug Approval120128710.070 Why?
Drug Discovery1201210670.060 Why?
Autopsy120079900.060 Why?
Neoplasm Recurrence, Local1202289250.060 Why?
Clinical Trials as Topic1201980160.060 Why?
Face120079830.050 Why?
Syndrome1200731950.050 Why?
Injections, Spinal120213160.050 Why?
Prospective Studies22022511820.050 Why?
Vincristine1202110400.040 Why?
Neoplasms22019205150.040 Why?
Mutation12022294410.040 Why?
Bone and Bones1200725660.040 Why?
Prednisone1202115490.040 Why?
Treatment Outcome22021621860.040 Why?
Cyclophosphamide1202121890.030 Why?
Doxorubicin1202122330.030 Why?
Piperidines1202215980.030 Why?
Pyrazoles1202219740.030 Why?
Disease-Free Survival1202170510.020 Why?
Pyrimidines1202229690.020 Why?
Recurrence1202182690.020 Why?
Infant, Newborn12007246450.020 Why?
Animals120191707330.020 Why?
Aged, 80 and over22021585030.020 Why?
United States Food and Drug Administration1201217450.020 Why?
Adult320222121280.010 Why?
Male320213510800.010 Why?
Follow-Up Studies12021392850.010 Why?
Aged220211626720.010 Why?
Middle Aged220212148680.010 Why?
Risk Factors12021707050.010 Why?
Young Adult12021561550.010 Why?
Female220213773280.010 Why?
United States12012676660.000 Why?
Sermer's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (64)
Co-Authors (7)
Similar People (60)
Same Department 
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.